Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing requirements.

Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year.

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.

Nvidia sold their stake in some high-flying stocks recently.

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.

The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.